K(
Therapeutic Areas
XOMA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Teprotumumab (Tepezza) | Thyroid Eye Disease (TED) | Approved |
| VX-548 | Acute Pain | Phase 3 |
| Ritlecitinib (Litfulo) | Alopecia Areata | Approved |
| Gevokizumab | Non-infectious Uveitis | Phase 3 |
| Bertilimumab | Bullous Pemphigoid | Phase 2 |
| XOMA 358 (RZ358) | Congenital Hyperinsulinism | Phase 2 |
Leadership Team at XOMA
JR
James R. Neal
Interim Chief Executive Officer
T(
Thomas (Tom) Burns
Chief Financial Officer and Corporate Secretary
BS
Bradley Sitko, CFA
Chief Investment Officer
OH
Owen Hughes
Executive Director
NH
Natasha Hernday
Executive Director, Corporate Operations & Marketing
BK
Barbara Kosacz
Chairperson of the Board of Directors
M(
Matthew (Matt) W. Perry
Director
BK
Bruce Kovner
Director
A(
Andrew (Andy) D. Sandler
Director
SL
Susan L. Kelly
Director